Background-Fight or flight heart rate (HR) increases depend on protein kinase A (PKA)-and calmodulin kinase II (CaMKII)-mediated enhancement of Ca 2+ uptake and release from sarcoplasmic reticulum (SR) in sinoatrial nodal cells (SANC). However, the impact of specific PKA and CaMKII phosphorylation sites on HR is unknown. Methods and Results-We systematically evaluated validated PKA and CaMKII target sites on phospholamban and the ryanodine receptor using genetically modified mice. We found that knockin alanine replacement of ryanodine receptor PKA (S2808) or CaMKII (S2814) target sites failed to affect HR responses to isoproterenol or spontaneous activity in vivo or in SANC. Similarly, selective mutation of phospholamban amino acids critical for enhancing SR Ca 2+ uptake by PKA (S16) or CaMKII (T17) to alanines did not affect HR in vivo or in SANC. In contrast, CaMKII inhibition by expression of AC3-I has been shown to slow SANC rate responses to isoproterenol and decrease SR Ca 2+ content. Phospholamban deficiency rescued SR Ca 2+ content and SANC rate responses to isoproterenol in mice with AC3-I expression, suggesting that CaMKII affects HR by modulation of SR Ca 2+ content. Consistent with this, mice expressing a superinhibitory phospholamban mutant had low SR Ca 2+ content and slow HR in vivo and in SANC.
C ardiac pacemaker cells control heart rate (HR) by generating spontaneous and repetitive action potentials. Action potential acceleration drives HR increases by a mechanism that relies on an intracellular Ca 2+ release and uptake process that is coupled to inward cell membrane ionic currents. These cellular mechanisms are often described separately as a Ca 2+ clock and a cell membrane clock. 1 Cardiac pacemaker cells can accelerate HRs in response to β-adrenergic receptor agonist stimulation as part of the physiological fight or flight response. β-Adrenergic receptor agonists increase the activity of protein kinase A (PKA) and calmodulin kinase II (CaMKII), serine-threonine kinases, in cardiac pacemaker cells. Both CaMKII 2 and PKA 3 contribute to fight or flight HR increases in response to isoproterenol injection or spontaneous ambulatory activity by catalyzing phosphorylation of proteins important for regulating intracellular Ca 2+ uptake and release from the sarcoplasmic reticulum (SR). However, to our knowledge, a systematic study of the effects of PKA and CaMKII phosphorylation on individual proteins that govern SR Ca 2+ uptake and release in sinoatrial node (SAN) pacemaker cells is lacking.
SR Ca 2+ release in SAN cells occurs through type 2 ryanodine receptors (RyR2). RyR2 Ca 2+ release is enhanced by phosphorylation of S2808 (by CaMKII and PKA) 4, 5 and by S2814 (by CaMKII). 6 The increased RyR2 Ca 2+ leak drives SAN cell membrane depolarizing inward current through the Na + /Ca 2+ exchanger. The Na + /Ca 2+ exchanger current (I NCX ) increases HR by hastening the late diastolic SAN cell membrane depolarization rate, causing higher frequency action potential triggering in SAN pacemaking cells. 7 We measured HRs and SAN automaticity in mice with RyR2 knockin mutations that disable PKA (S2808A)-and CaMKII (S2814A)catalyzed phosphorylation at these sites.
SR Ca 2+ uptake in SAN cells is governed by a protein complex that includes phospholamban (PLN) and the sarcoplasmic endoplasmic reticulum ATPase (SERCA2a). [1] [2] [3] PLN is a Heart Rate and Single Site Mutation negative regulator of SERCA2a under basal conditions. 8 PLN phosphorylation by PKA (at S16) or CaMKII (at T17) leads to loss of SERCA2a inhibition and increased Ca 2+ transport from the cytoplasm to the SR. We studied mice and isolated SAN cells lacking PLN (Pln −/− ), expressing mutant PKA-resistant PLN (S16A), CaMKII-resistant PLN (T17A), and mice with a superinhibitory PLN mutant, N27A, which constitutively suppresses SERCA2a even after PKA-and CaMKII-catalyzed phosphorylation. [9] [10] [11] Despite the important roles of PKA and CaMKII in activating the Ca 2+ clock and promoting fight or flight HR increases, the relative importance of PKA and CaMKII sites on RyR2 and PLN are unknown; furthermore, the potential for any particular site to exert a controlling influence over fight or flight physiology in vivo and in vitro is untested. To address this knowledge gap, we used a cohort of genetically modified mouse models in which CaMKII and PKA phosphorylation sites were specifically ablated to interrogate the role of each site and determine if any of these SR protein sites exercises a decisive influence on HR responses to isoproterenol (ISO) or activity.
Here we show that none of the 4 well-validated PKA or CaMKII phosphorylation sites on PLN and RyR2 are individually required for physiological rate increases in isolated SAN cells or in vivo in response to spontaneous activity or isoproterenol injection. Although no single phosphorylation site in our models had a controlling role in HR acceleration, we found that superinhibitory PLN mutants significantly lowered SR Ca 2+ content and limited HR acceleration, whereas PLN deficiency prevented reduction in SR Ca 2+ content and normalized HR acceleration during CaMKII inhibition. Taken together, our data show that loss of any single site failed to affect HRs and suggest that fight or flight HR increases are built from redundant PKA and CaMKII catalyzed phosphorylation target proteins. Our data are consistent with a concept where CaMKII inhibition slows HR by lowering the pool of SR Ca 2+ in cardiac pacemaker cells.
Methods

Genetically Modified Mice
The cohort of mice used in this study is shown in Table. Pln −/− , S16A, T17A, N27A, and wild-type (WT)-PLN mice were obtained from MMRRC (Columbia, MO), but were originally developed by the Kranias group. [9] [10] [11] All of these mice were engineered by transgenic expression of WT and mutant PLN on a Pln −/− background. The lines were selected for similar transgenic expression levels of S16A, T17A, N27A, and WT-PLN. 10, 11 The littermate controls S16A(−) and T17A(−) are Pln −/− . WT mice in the C57 background are designated WT, and WT-Pln indicates controls where a WT Pln transgene was expressed in a Pln −/− background. The S2808A and S2814A mice were developed by knockin replacement of the designated alleles, as described. 12, 13 Pln −/− mice were interbred with mice overexpressing CaMKII inhibitor peptide AC3-I 2 (AC3-IxPln −/− ) and mice overexpressing scrambled control peptide AC3-C (AC3-CxPln −/− ) for >10 generations, and the genetic identity of Pln −/− pups with transgenic expression of AC3-I or AC3-C was confirmed using PCR, as described. 14
Telemetry ECG and Spontaneous Activity Recording
Surgical implantation of ECG and ambulatory activity-sensing and recording telemeters was conducted as described 15 (see methods in the Data Supplement for detail).
SAN Cell Isolation, Action Potential, I f , I NCX , and SR Ca 2+ Content Recordings
Isolation of single SAN cells from mice, action potential recordings, I f , and I NCX current measurements from single SAN cell were performed as previously published 2, 16, 17 (see methods in the Data Supplement for detail).
Briefly, SAN cells were identified by their characteristic morphology (spindle or spider shape) and spontaneous activity. SAN cells were also identified electrophysiologically by typical spontaneous action potentials with slow depolarizing phase 4 and the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel current (I f ).
Spontaneous action potentials were recorded in current clamp (I=0) mode using the perforated (amphotericin B) patch-clamp technique on single SAN cell at 36±0.5°C in Tyrode's solution. The pipette was filled with 130 mM potassium aspartate, 10 mM NaCl, 10 mM HEPES, 0.04 mM CaCl 2 , and amphotericin B 240 μg/mL. I f was recorded in voltage clamp mode. Membrane potential was held at −35 mV, and the voltage steps were applied for 5 s ranging from −125 to −45 mV in 10 mV increments, or vice versa.
I NCX was recorded using whole-cell patch clamp technique at 36±0.5°C. The external solution contained the following: 140 mM NaCl, 1.0 mM MgCl 2 , 5.0 mM HEPES, 2.5 mM CaCl 2 , 1.0 mM BaCl 2 , 10 mM glucose, 10 μM nitrendipine, and 10 μM strophanthidin. The internal solution contained the following 110 mM CsCl, 10 mM NaCl, 5.0 mM glucose, 1.0 mM CaCl 2 , 0.4 mM MgCl 2 , 10 mM HEPES, 20 mM TEA chloride, and 5.0 mM EGTA. Membrane currents were elicited by a command ramp of 2 s from +80 to −120 mV. Holding potential was −80 mV. The protocol was applied every 10 s. Recordings were taken when 5 consecutive ramp recordings showed nearly identical currents. I NCX was measured as the Ni-sensitive current. NiCl 2 (5 mmol/L) was added to define the fraction of current from NCX (the difference currents between total currents and post-Ni 2+ currents from the same cell).
WHAT IS KNOWN
• Fight or flight heart rate increases depend on protein kinase A (PKA) and Ca 2+ /calmodulin kinase II (CaMKII) mediated enhancement of Ca 2+ uptake and release from sarcoplasmic reticulum (SR) in sinoatrial nodal pacemaker cells (SANC).
• CaMKII inhibition slows fight or flight heart rate increases.
• The impact of individual PKA and CaMKII phosphorylation sites regulating SR Ca 2+ uptake and release on heart rate modulation is unknown.
WHAT THE STUDY ADDS
• We used a suite of genetically modified mice to evaluate PKA and CaMKII target sites on phospholamban (PLN), which modulates SR Ca 2+ uptake, and the ryanodine receptor (RyR2), which mediates SR Ca 2+ release, in SANC.
• We found that ablation of individual RyR2 or PLN PKA or CaMKII target sites failed to affect heart rate in vivo or in SANC.
• Our data suggest CaMKII inhibition slows heart rate by reducing SR Ca 2+ content and that a minimum SR Ca 2+ content is required in SANC for physiological fight or flight heart rate increases. SR Ca 2+ content was measured by integrating the I NCX in response to a spritz of caffeine, as described. 2 Briefly, cells were loaded with Ca 2+ by repetitive voltage command steps (300 ms, 0.5 Hz) from -80 to 0 mV at 36±0.5°C. The bath solution contained 137 mM NaCl, 10 mM HEPES, 10 mM glucose, 1.8 mM CaCl 2 , 0.5 mM MgCl 2 , and 25 mM CsCl. The intracellular pipette solution contained 120 mM CsCl, 10 mM TEA, 1.0 mM MgATP, 1.0 mM NaGTP, 5.0 mM phosphocreatine, 10 mM HEPES, and Indo-1 0.2. After >15 conditioning voltage command steps, the SAN cell membrane was held at −80 mV and a caffeine (20 mmol/L) spritz was locally applied. The resultant I NCX was integrated and normalized to cell size.
Data Analysis and Statistics
Spontaneous action potential rates were analyzed using Clampfit 10. Arbitrary activity counts from the telemetry ECG recording system (Data Sciences International) were binned for analysis, with a bin width of 5 counts (see methods in the Data Supplement for detail). The mean HR was determined separately for each mouse and activity bin. One-way analysis of variance combined with Holm-Sidak test was used when >2 groups were compared. Student's t test was used when appropriate; paired t test was used when comparing before and after treatment data on the same cells; the unpaired t test was used for comparing data from 2 groups. Data were tested for normal distribution (Shapiro-Wilk [normality test] or Brown-Forsythe [equal variance test], as appropriate). A signed-rank test was used to generate a P value for nonparametric data. We rejected the null hypothesis for P<0.05.
Results
Loss of RyR2 S2808 or S2814 Failed to Affect HRs In Vivo
We studied mice with knockin mutations that selectively eliminated a validated PKA (S2808A) 5, 12 or CaMKII phosphorylation site (S2814A). 6, 13 The S2808A and S2814A mice had normal HR acceleration compared with WT control in response to isoproterenol injection ( Figure 1A and 1B) or spontaneous activity ( Figure 1C and 1D). These findings suggest that loss of RyR2 S2808 or S2814 alone are insufficient to impair the in vivo HR response to catecholamine or physiological stress related to spontaneous ambulatory activity.
Loss of RyR2 S2808 or S2814 Did Not Affect SAN Cell Rates
HR is a complex integrated response where multiple inputs converge on SAN cells to drive basal and fight or flight HR responses. 18 We found that SAN cells isolated from S2808A and S2814A mice had similar action potential rates at baseline, in the absence of catecholamine agonist stimulation, and after isoproterenol compared with SAN cells isolated from WT littermates (Figure 2A and 2B). These results showed that neither loss of S2808 nor S2814 on RyR2 was sufficient to disrupt SAN cell rate responses, suggesting that the observed preservation of in vivo HR responses in S2808A and S2814A was not the result of compensatory changes in SAN cell innervation. The results to date, using S2808A and S2814A knockin mice, showed that loss of these RyR2 target sites individually was inadequate to affect HR, suggesting that PKA and CaM-KII cannot modulate HR by affecting SR Ca 2+ release through post-translational modification of a single RyR2 site.
Loss of RyR2 S2814 Increases SAN Cell SR Ca 2+ Content
RyR2 phosphorylation by PKA and CaMKII can increase late diastolic SR Ca 2+ leak, 6, 12, 19, 20 potentially reducing SR Ca 2+ content. We measured SAN cell SR Ca 2+ content by integrating the I NCX after caffeine-triggered SR Ca 2+ release and found that S2814A SAN cells had relatively increased basal SR Ca 2+ content compared with S2808A and controls ( Figure 2C and . These data showed that loss of a PKA site (S2808) was insufficient to affect basal SAN cell SR Ca 2+ content or the physiological increase in SR Ca 2+ content after isoproterenol, but loss of the S2814 CaMKII site did result in a modest but significant increase in basal SAN cell SR Ca 2+ content.
Loss of PLN Maximized SR Ca 2+ Content Without Affecting HR
We next turned our attention to processes affecting SR Ca 2+ uptake. PKA and CaMKII catalyze phosphorylation of PLN at single, distinct, extensively validated sites, leading to loss of negative regulation of SERCA2a by PLN and increased SR Ca 2+ uptake. 2, 3, 8 As a first step, we assessed whether loss of PLN affects HR or SR Ca 2+ content in SAN cells. We found that Pln −/− mice had HRs that were similar to WT controls at rest and in response to isoproterenol ( Figure 3A and 3B), similar to earlier descriptions, 9 or in response to spontaneous activity ( Figure 3C ). SAN cells isolated from Pln −/− and WT-Pln mice also exhibited similar resting and isoproterenol-stimulated rates ( Figure 3D ), mirroring the in vivo HR responses to isoproterenol or activity. We next measured SR Ca 2+ content in isolated SAN cells at baseline and after isoproterenol. The SR Ca 2+ content in WT SAN cells was significantly increased over baseline by isoproterenol exposure. In contrast, SR Ca 2+ content in Pln −/− SAN cells was replete under basal conditions and not further increased by isoproterenol ( Figure 3E and 3F). We interpreted these findings as confirming that loss of PLN expression did not affect HR responses in vivo nor in isolated SAN cells but effectively released SERCA2a from inhibition, increasing basal SR Ca 2+ content in SAN cells, similar to established actions in ventricular myocytes. 21
Expression of S16A or T17A Did Not Impair Heart or SAN Cell Rates
We next turned our attention to extensively characterized mice where Pln was transgenically replaced by WT Pln or mutant Pln lacking either the PKA (S16A) or CaMKII (T17A) sites. 10 We found that mice transgenically expressing PLN S16A or T17A had normal HR acceleration in response to isoproterenol injection ( Figure 4A and 4B) ; mice with transgenic expression of WT, S16A, and T17A had equivalent rate responses to spontaneous activity ( Figure 4C and 4D). SAN cells isolated from S16A and T17A mice had similar action potential rates at baseline and after isoproterenol compared with SAN cells isolated from mice with transgenic WT PLN expression ( Figure 5A and 5B) . We next checked SR Ca 2+ content at baseline and in response to ISO in SAN Neither PLN mutation affected SR Ca 2+ content at baseline, but each mutation abolished the physiological increase in SR Ca 2+ content after ISO ( Figure 5D ). These data suggest that PLN and PKA and CaMKII sites on PLN are individually dispensable for fight or flight HR responses in vivo and in isolated pacemaker cells.
SAN Rate Slowing by CaMKII Inhibition Required PLN
SAN cell CaMKII inhibition by expression of a CaMKII inhibitory peptide, AC3-I, compresses the dynamic range of HR acceleration by ≈50% 2 ; however, the mechanism of action for AC3-I expression in SAN cells to slow HR is incompletely understood. AC3-I expression in isolated SAN cells 2 and ventricular myocytes 22 reduces SR Ca 2+ filling in response to isoproterenol ( Figure 6A ), suggesting the possibility that SAN SR Ca 2+ repletion, above a threshold, is required for physiological rate acceleration and that the HR slowing actions of CaMKII inhibition are related, at least in part, to reduction in SR Ca 2+ content below a critical threshold required for physiological HR increases. Based on the hypothesized association between SR Ca 2+ content and SAN rate responses to isoproterenol, we next isolated SAN cells from Pln −/− mice interbred with AC3-I transgenic mice (AC3-IxPln −/− ) or interbred with mice transgenically expressing an inactive control peptide, AC3-C (AC3-CxPln −/− ) 14, 22 to determine whether CaMKII inhibition affected SR Ca 2+ content in the absence of Pln, potentially under conditions of replete SR Ca 2+ content. The SR Ca 2+ content was replete at baseline and not further increased by isoproterenol in SAN cells isolated from AC3-IxPln −/− and AC3-CxPln −/− mice ( Figure 6A ), indicating that reduced SR Ca 2+ content in SAN cells expressing AC3-I was repaired by loss of PLN expression.
These interbred mice provided a new model to test whether the relationship between AC3-I expression and reduced SR Ca 2+ content was essential for slower SAN rates identified in AC3-I transgenic mice. 2, 22, 23 We found that all SAN cells had similar resting and isoproterenol-stimulated rates compared with WT and Pln −/− SAN cells (Figures 6B, 6C , and 3D). We compared these SAN cell rates with published rates from AC3-I SAN cells ( Figure 6C ) to demonstrate the ISO rate recovery response to Pln knockout. The interbred AC3-IxPln −/− mice unexpectedly exhibited atrioventricular nodal conduction block that prevented a meaningful assessment of in vivo HRs (Figure 1 in the Data Supplement). These data show that CaMKII inhibition does not slow isoproterenol-stimulated In vivo basal heart rate and response to isoproterenol (ISO) or activity were not altered in S16A or T17A mice. A, Representative ECG telemetry recording traces (at baseline and after ISO injection) from T17A (top), S16A (middle), and S16A(−) (bottom) mice. B, Summary data of ECG telemetry recorded heart rate at baseline and in response to ISO stimulation in S16A, T17A, and their littermate control Pln −/− background mice (S16A(−) and T17A(−)). The number of mice used in the summary data is indicated by numerals in the corresponding bars. *P<0.05, **P<0.01, ***P<0.001, paired Student's t test, Wilcoxon signed-rank test was used for T17A group data. C, Activity-related heart rate changes in S16A and WT-Pln control mice, n=3 to 20. D, Activity-related heart rate changes (see Methods) in T17A and WT-Pln control mice, n=4 to 20. Heart Rate and Single Site Mutation SAN cell rates in the absence of PLN and are consistent with the idea that CaMKII inhibition hinders HR acceleration by reducing SR Ca 2+ content.
HR Slowing in Mice With Super Inhibitory PLN
Based on our findings that the HR slowing from AC3-I expression was rescued in mice with a Pln −/− background, we next asked if a superinhibitory PLN mutant (N27A) that inhibits SERCA2a despite phosphorylation 11 would depress HR. We found that N27A mice had significantly reduced HRs at baseline and in response to isoproterenol or spontaneous activity ( Figure 7A-7C ). We next isolated SAN cells from N27A and Pln −/− littermate mice, as well as WT-Pln mice, to test whether defective chronotropic performance was present in SAN cells. SAN cells isolated from N27A mice had significantly reduced resting rates and impaired isoproterenol rate responses compared with WT-Pln control and littermate Pln −/− SAN cells ( Figures 5A, 6B, 7D, and 7E ). Finally, we found that SR Ca 2+ content was reduced at baseline and was not significantly increased by isoproterenol in N27A SAN cells ( Figure 7F ). We interpreted these findings to show that enhanced PLN-mediated SERCA2a inhibition could constrain SAN cell SR Ca 2+ filling and reduce physiological HR responses. We summarized the SR Ca 2+ content findings for all models, before and after ISO, to facilitate comparisons (Table in the Data Supplement) .
HCN (I f ) Currents and NCX Currents Were Not Altered by PLN Deletion or Mutation
We recorded I f currents from SAN cells isolated from WT-Pln, Pln −/− , and N27A mice ( Figure 8A and 8B ). There were no difference in I f density between those groups. Similarly, we did not find significant differences in I NCX current density between those groups ( Figure 8C and 8D ).
Discussion
HR Is Protected by Partially Redundant Mechanisms
Given the importance of HR to survival, it is not surprising that the SAN cellular mechanisms for maintaining and accelerating HR are reinforced by redundancy. However, certain components of the pacemaking machinery exert clear and quantifiable contributions to HR maintenance and acceleration because their removal or inactivation causes loss of basal HR or impairs HR increases. The drug ivabradine slows HR, at least in part, by antagonist actions on HCN4. 24 Loss of the NCX, [25] [26] [27] inhibition of the mitochondrial Ca 2+ uniporter, 16 and application of toxins that prevent SR Ca 2+ uptake (thapsigargin) 16, 28 and release (ryanodine) 16, 28 reduce or eliminate HR acceleration. These latter examples comprise some of the evidence in support of the Ca 2+ clock concept for pacemaker cell automaticity. 1 Mouse models of PKA 29 and CaMKII 2 inhibition by α-myosin heavy chain promoter-driven transgenic expression of kinase-inhibitory peptides maintain normal resting HRs but exhibit selective loss of HR acceleration after isoproterenol injection. Based on the now established role of SR Ca 2+ uptake and release to affect SAN rates and the 
RyR2 Phosphorylation Sites Do Not Control HR Individually
We found that loss of either RyR2 phosphorylation site was insufficient to affect basal HR or HR acceleration in response to isoproterenol injection or spontaneous activity. Furthermore, the behaviors of isolated SAN cells mirrored in vivo responses in that resting and isoproterenol-accelerated automaticity was similar between mutant and control preparations. Our findings are partially confirmed by one study using the same S2808A mice 30 but different than another report showing S2808A mice have defective HR acceleration. 31 Although we are uncertain about the basis for the discrepant findings, we note that our study and the work by Shan et al 31 used the same isoproterenol dosing for in vivo studies, although HRs in our mice, implanted with ECG and activity telemeters, were measured in the absence of anesthesia. It is also possible that the lack of alignment between our results and the findings of Shan et al 31 are because of undetermined differences in the mouse models. Taken together, we think our new data constitute strong evidence that RyR2 S2808 and S2814 are individually dispensable for normal resting HRs and for physiological HR responses. Furthermore, additional RyR2 phosphorylation sites, already known (eg, S2030 32 ) or yet to be identified, may contribute to HR control. In contrast to the lack of effect on HR, our data suggest that the S2814 site is more important than S2808 for determining basal SR Ca 2+ leak because S2814A SAN cells show elevated SR Ca 2+ content compared with S2808A and WT counterparts.
A Role for PLN in HR?
We found that Pln −/− mice and SAN cells isolated from Pln −/− mice have similar resting heart and automaticity rates compared with WT and transgenic controls. WT mice had equivalent baseline HRs and responses to isoproterenol. 9 We interpret these data to suggest that PLN plays a permissive role, perhaps to set SR Ca 2+ content to a physiological set point, but is not required for basal or physiological HR responses. We hypothesize that phosphorylation at either S16 or T17 is not required to disinhibit SERCA2a sufficiently to sustain such a set point. In contrast, mice with superinhibitory PLN (N27A) had severely impaired resting, isoproterenol-and activity-stimulated HRs, consistent with earlier reports. 11, 16 These data show that extreme inhibition of SER-CA2a activity does impact HR.
CaMKII Inhibition Does Not Affect HR in Mice Lacking PLN
SAN CaMKII activity is critical for sustaining the full dynamic range of HR under physiological stress but is dispensable for maintaining resting heart or SAN rates. 2 We tested the idea that CaMKII actions to affect HR in SAN cells operated by a PLN or PLN-associated pathway by interbreeding AC3-I and Pln −/− mice. Surprisingly, loss of Pln allowed AC3-I-expressing hearts and SAN cells to achieve a HR similar to WT. We interpret this result to suggest that lowering of SR Ca 2+ content in AC3-I transgenic mice may be a key component of the mechanism of HR slowing by CaMKII inhibition. We originally reported that SR Ca 2+ content is reduced in AC3-I SAN cells, 2 and here we show that AC3-I expression is not capable of reducing SAN cell SR Ca 2+ content in the absence of PLN. We speculate that AC3-I expression reduces SR Ca 2+ content below a set point required to sustain physiological rate increases and that loss of PLN supersedes the SR Ca 2+ -lowering consequences of AC3-I expression. Based on our published (Wu et al, 2 see Figure 6C ) and new data ( Figures 2D, 3F , 5D, 6A, and 7F), we expect that SAN cell SR Ca 2+ content <1.0 C/F, assessed as a caffeine releasable store and interrogated by integration of I NCX , is insufficient to support physiological HR responses (Table in the Data Supplement) . It is also possible that CaM-KII contributes to SR Ca 2+ filling by actions at extra PLN targets, such as mitochondria or novel sites on RyR2, PLN, and RyR2-associated proteins.
